LAWSUITS FILED AGAINST PLL, SAVA and SPPI - Jakubowitz Law Pursues Shareholders Claims
Back to Newsroom
Mentioned in this Article

LAWSUITS FILED AGAINST PLL, SAVA and SPPI - Jakubowitz Law Pursues Shareholders Claims

Friday, September 10, 2021 10:15 AM
Share this article now
Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / September 10, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Piedmont Lithium Inc. (NASDAQ:PLL)

CONTACT JAKUBOWITZ ABOUT PLL:
https://claimyourloss.com/securities/piedmont-lithium-inc-loss-submission-form/?id=19476&from=1

Class Period : March 16, 2018 - July 19, 2021

Lead Plaintiff Deadline : September 21, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Piedmont has not, and would not, follow its stated steps or timeline to secure all proper and necessary permits; (2) Piedmont failed to inform relevant people and governmental authorities of its actual plans; (3) Piedmont failed to file proper applications with relevant governmental authorities (including state and local authorities); (4) Piedmont and its lithium business does not have “strong local government support”; and (5) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times.

Cassava Sciences, Inc. (NASDAQ:SAVA)

CONTACT JAKUBOWITZ ABOUT SAVA:
https://claimyourloss.com/securities/cassava-sciences-inc-loss-submission-form/?id=19476&from=1

Class Period : February 2, 2021 - August 24, 2021

Lead Plaintiff Deadline : October 26, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) the quality and integrity of the scientific data supporting Cassava’s claims for simufilam’s, a small molecule drug designed to treat Alzheimer's disease, efficacy had been overstated; (b) the scientific data supporting Cassava’s claims for simufilam’s efficacy were biased; and (c) as a result of the foregoing, Defendants’ positive statements during the Class Period about the Company’s business metrics and financial prospects and the likelihood of Food and Drug Administration approval were false and misleading and/or lacked a reasonable basis.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)

CONTACT JAKUBOWITZ ABOUT SPPI:
https://claimyourloss.com/securities/spectrum-pharmaceuticals-inc-loss-submission-form/?id=19476&from=1

Class Period : December 27, 2018 - August 5, 2021

Lead Plaintiff Deadline : November 1, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the manufacturing facility for ROLONTIS, an investigational granulocyte-colony stimulating factor analog, maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration would approve the ROLONTIS biologics license application ("BLA") in its current form; (iii) Spectrum had therefore materially overstated the ROLONTIS BLA’s approval prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law
 

Jakubowitz Law
Back to Newsroom
{{msgBox.title}}

that

Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |   Terms and Conditions